What You Need To Know… Breast Cancer Statistics

• Breast cancer is the leading cause of cancer death among in women worldwide.


• Among US women ages 20 to 59, breast cancer is the leading cause of death.


• One out of every eight American women will develop breast cancer at some point in her life.


• All women, regardless of family history, are at risk for breast cancer. In fact, in 90 percent of cases, there is no family history of the disease.


• 70% of women who develop breast cancer have no identifiable risk factors, other than age.


• Approximately 40,000 deaths occur each year from breast cancer in the United States alone - 39,600 women and 400 men.

These breast cancer statistics are cause for alarm. But our new breast health screening test is cause for celebration.

A cervical Pap test has become a routine part of your annual check-up because it identifies abnormal cell activity that could eventually become cancerous. Since the cervical Pap test was developed fifty years ago, statistics show that deaths from cervical cancer have decreased more than 80%, thanks largely to the Pap test. By comparison, only modest progress has been made in reducing the occurrence of breast cancer, and breast cancer statistics have stayed at an alarmingly high level…until now.

Over the coming years, the HALO Breast Pap Test will become routine, too. Similar to the cervical Pap test, HALO identifies abnormal cells in breast fluid long before cancer might develop and years before a mammogram or a manual exam could detect an actual lump.

In clinical studies that followed over 20,000 women for up to 25 years, statistics revealed that women had a 400-500% higher risk of developing breast cancer if abnormal cells were detected in their breast ducts. ^{1 2 3 4}

The World’s First Automated Pap Test for your Breasts

Developed by Neomatrix, the HALO Breast Pap Test is an FDA-approved early warning test for your breasts. It is a simple, noninvasive procedure your doctor can perform in just five minutes. Like the cervical Pap test, the HALO Breast Pap Test gives you and your doctor more precious time to take preventive measures that can reduce your risk of developing breast cancer. One exam at a time, you and other proactive women can help improve breast cancer statistics forever.

What Your Doctor Needs to Know…

The HALO Breast Pap Test: A Fact Sheet for Doctors

Click here to download for your doctor.

There is a good chance that your doctor doesn’t know about the HALO Breast Pap Test, so it is up to you to enlighten her. Please download and print this important fact sheet. Give it to your doctor during your next visit, and let her know that you want the HALO Breast Pap Test to become a routine part of your annual physical. Be proactive about your personal breast health care, and help countless other women, too. Frightening statistics about breast cancer aren’t written in stone; you have the power to change them.

Don’t confuse the HALO® Breast Pap Exam With “Ductal Lavage”

You or your doctor may be familiar with “Ductal Lavage,” a breast test that was introduced by another company several years ago. Time-consuming and expensive, Ductal Lavage takes up to one hour to complete and isn’t easy for the patient to endure. The FDA approval for Ductal Lavage restricts its use to women already known to be at high risk for breast cancer, whereas HALO is approved for use in women at normal risk and with no symptoms of the disease. The HALO Breast Pap Test is the world’s first fully automated breast assessment test for detection of early breast cancer signs and symptoms. Women appreciate the fact that it is economical, noninvasive and takes just five minutes to perform.

Neomatrix hopes that this information about Breast Cancer Statistics and the HALO Breast Pap Test has empowered you to be more assertive about your personal breast health management so that you won’t become one of the statistics.

Click here to read more about the HALO Breast Test

Click here to view our new patient video

Click here for procedure details

1 Hartmann LC, Sellers TA, Frost MA, et al. Benign Breast Disease and the Risk of Breast Cancer. NEJM 2005;353(3):229-237

2 Wrensch MR, Petrakis NL, et al. Breast cancer incidence in women with abnormal cytology in nipple aspirates of breast fluid. Am J Epidemiol 1992;135(2):130-141

3 Fabian CJ, Kimler BF. Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail Risk Model. JNCI 2000; 92(15):1217-1227

4 Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. NEJM 1985;312(3):146-15